{"prompt": "['EudraCT Number 2019-002880-82, IRAS Number 1003208', 'CONTENTS', '1.', 'Study Synopsis', '3', '2.', 'Glossary of Terms', '5', '3. Background & Rationale', '8', '3.1 Effectiveness of current treatments', '8', '3.2 Rationale', '9', '3.3 Pilot data', '10', '3.4. Rationale for using continuous glucose monitoring (CGM), dietary assessment and vascular', 'studies', '11', '3.5 Future work', '12', '4. Trial Objectives and Design', '12', '4.1. Trial Objectives', '12', '4.1.1 Primary objective', '12', '4.1.2 Secondary objectives (endpoints detailed below in 4.2.2)', '13', '4.2 Trial endpoints', '13', '4.2.1 Primary endpoint', '13', '4.2.2 Secondary endpoints', '13', '4.3 Trial Design', '14', '4.4 Trial Flowchart', '15', '5. Trial Medication', '16', '5.1 Investigational Medicinal Product', '16', '5.1.1 UDCA', '16', '5.1.2 Metformin', '16', '5.2 Dosing Regimen', '16', '5.3 IMP Risks', '17', '5.4 Drug Accountability', '17', '5.5 Storage of IMP', '18', '5.6 Participant Compliance', '18', '5.7 Concomitant Medication', '18', '6. Selection and Withdrawal of Participants', '18', '6.1 Inclusion Criteria', '18', '6.2 Exclusion Criteria', '19', '6.3 Selection of Participants', '19', '6.4 Randomisation Procedure / Code Break', '20', '6.5 Withdrawal of Subjects', '20', '6.6 Expected Duration of Trial', '21', '7.', 'Trial Procedures', '22', '7.1 By Visit', '23', '7.1.1 Identification and Informed Consent', '23', '7.1.2 Baseline', '24', '7.1.3 Follow up 1', '24', '7.1.4 Follow up 2', '25', '7.1.5 Birth and immediate postpartum period', '25', '7.1.6 Post birth', '26', '7.2 Laboratory Tests', '26', '8. Assessment of Efficacy', '27', '8.1 Primary Efficacy Parameters', '27', '8.2 Secondary Efficacy Parameters', '27', '8.3 Procedures for Assessing Efficacy Parameters', '27', '9. Assessment of Safety', '28', '9.1 Specification, Timing and Recording of Safety Parameters', '28', '9.2 Procedures for Recording and Reporting Adverse Events', '29', '9.2.1 Reporting Responsibilities', '29', '9.2.2 Definition of causality', '30', '9.2.3 Severity', '30', 'GUARD protocol V1.0 11Mar20', 'Page 6 of 53']['EudraCT Number 2019-002880-82, IRAS Number 1003208', '9.2.4 Expectedness', '30', '9.2.5 Adverse events that do not require reporting', '30', '9.3 Treatment Stopping Rules', '31', '10. Statistics', '31', '10.1 Sample Size', '32', '10.2 Randomisation', '32', '10.3 Analysis', '32', '10.4 Procedures for dealing with missing data, unused data and false data52', '33', '11. Trial management and oversight', '33', '11.1 Overview of trial management', '33', '11.2 Trial Management Group', '34', '11.3 Trial Steering Committee', '34', '11.4 Independent Data Monitoring Committee', '34', '11.5 Patient and Public Involvement', '35', '12. Ethics & Regulatory Approvals', '35', '12.1 Ethical issues', '35', '13. Quality Assurance', '36', '13.1 Direct Access to Source Data and Documents', '36', '13.2 Trial monitoring', '36', '14. Data Handling', '36', '15. Data Management', '37', '16. Publication Policy', '38', '17. Insurance / Indemnity', '38', '18. Financial Aspects', '38', '19. Mechanistic Sub-study: GUARD MEC', '39', '19.1 Objectives', '39', '19.2 Exploratory endpoints', '39', '19.3 Design', '39', '19.4 Inclusion Exclusion criteria', '40', '19.5 Recruitment & assessments', '41', '19.6 Laboratory details', '44', '19.7 Reporting of Adverse Events', '44', '20. References', '46', '21. Appendixes', '50', '22. Record of protocol amendments', '52', '23. Signatures', '53', 'GUARD protocol V1.0 11Mar20', 'Page 7 of 53']\n\n###\n\n", "completion": "END"}